Porrozzi R, Pereira M S, Teva A, Volpini A C, Pinto M A, Marchevsky R S, Barbosa A A, Grimaldi G
Departamento de Imunologia, FIOCRUZ, Av. Brasil 4365, 21045-900 Rio de Janeiro, RJ, Brazil.
Trans R Soc Trop Med Hyg. 2006 Oct;100(10):926-37. doi: 10.1016/j.trstmh.2005.11.005. Epub 2006 Feb 7.
Visceral leishmaniasis (VL) was experimentally induced in rhesus macaques (Macaca mulatta) by intravenously inoculating 2 x 10(7)amastigotes/kg of body weight of Leishmania infantum. The macaques developed a systemic disease showing characteristic features of human VL such as fever, diarrhoea, body weight loss, anaemia, hypergammaglobulinaemia and transient lymphocytosis, as well as lymph node, liver and/or spleen enlargement. Nine weeks after infection, one primate showed pronounced weight loss, became moribund and was euthanized. The necropsy findings included granulomas composed of parasite-containing macrophages, lymphocytes and plasma cells in the liver, spleen and lymph nodes. The remaining macaques had a sustained course of infection but developed a mild-to-moderate illness that subsequently showed evidence of self-cure. Of note, pathological findings included a typical cell-mediated immunity-induced granulomatous reaction that had an effect on the control of parasite replication. All infected monkeys responded with increased production of anti-Leishmania-specific IgG antibodies. Despite the fact that clinical resistance to L. infantum was not consistently associated with a parasite-specific cell-mediated immune response, drug-cured macaques from the primary infection acquired immunity to homologous re-infection. These findings point to the feasibility of using the L. infantum macaque model for pre-clinical evaluation of novel chemotherapeutics or vaccine candidates for human VL.
通过静脉注射每千克体重2×10⁷个婴儿利什曼原虫无鞭毛体,在恒河猴(猕猴属)中实验性诱导内脏利什曼病(VL)。这些恒河猴出现了一种全身性疾病,表现出人类VL的特征性症状,如发热、腹泻、体重减轻、贫血、高球蛋白血症和短暂性淋巴细胞增多,以及淋巴结、肝脏和/或脾脏肿大。感染九周后,一只灵长类动物体重明显减轻,濒死,随后实施安乐死。尸检结果包括在肝脏、脾脏和淋巴结中由含寄生虫的巨噬细胞、淋巴细胞和浆细胞组成的肉芽肿。其余的恒河猴有持续的感染过程,但发展为轻度至中度疾病,随后显示出自愈的迹象。值得注意的是,病理结果包括典型的细胞介导免疫诱导的肉芽肿反应,该反应对控制寄生虫复制有作用。所有受感染的猴子抗利什曼原虫特异性IgG抗体产生增加。尽管对婴儿利什曼原虫的临床抵抗力并不总是与寄生虫特异性细胞介导免疫反应相关,但初次感染经药物治愈的恒河猴获得了对同源再感染的免疫力。这些发现表明,利用婴儿利什曼原虫恒河猴模型对人类VL的新型化疗药物或候选疫苗进行临床前评估是可行的。